Is breast cancer advocacy distorting the cancer budget to the disadvantage of other tumours? by Cassidy, Jim
Cancer is a common disease in all Western nations. Current
estimates are that about one in three will develop cancer and
about one in four will die from the disease. The ageing
population means that this problem is likely to become even
more prevalent. In contrast, it is hoped that the impact of
screening and early detection of disease is that we will see
more cancers at an earlier and hence more curable stage in
their evolution.
I think it is fair to say that cancer has (or will) touch all of us in a
direct way. Hence, we all have close friends or family members
who have the disease. Therapy for cancer is unfortunately often
palliative because of late presentation and our lack of curative
options for most metastatic common solid cancers, so there is
much emotion surrounding cancer; some would suggest that
this is out of proportion to the prevalence of the disease.
Cardiovascular disease kills more people, but it is somehow less
emotive to the general public. People who have a myocardial
infarction do not ask ‘How long have I got doc?’, but cancer
patients very often do ask for this kind of information.
The most common cancers that we encounter are breast,
lung, colorectal and urological. It is clear that the
demographics of each of these diseases are distinct. Certain
cancers have a predilection for age, sex and social class.
Breast cancer is a disease predominantly of middle class
females. It is actually commoner with increasing age, but
middle-aged women still suffer a high proportion of the
burden. Lung cancer almost exclusively occurs in smokers,
and it has a higher incidence in lower social classes.
Colorectal cancer is slightly more common in well educated
people with sedentary occupations. Urological cancer (the
bulk of which is prostate cancer) affects older males.
Cancer therapy budgets have in the past been (and continue to
be) established with little regard for the prevalence of the
disease. In fact, the therapy budgets tend to reflect the number
and type of options that we have available, and so breast
cancer is out in front because we have multiple modalities of
therapy (screening, surgery, radiotherapy, hormones and
chemotherapy). This is in stark contrast to lung cancer, in
which (until very recently) most patients presented late, had
multiple smoking-induced comorbidities and could only be
offered palliative care. Perhaps as we develop more and better
therapies for other cancers, some of the therapy budget
imbalance will iron out. However, some would advocate that in
a disease in which the patient’s lifestyle is a major causative
factor (for instance, smoking and lung cancer), the burden of
care should not be borne by the rest of society. I think this is a
dangerous argument. How do we know that lifestyle does not
influence all cancer incidence? Perhaps we should not treat
any of the sufferers, and what about cardiovascular disease?
The other factor that definitely plays a role is the activities of
pressure groups or patient advocacy organizations. The
demographics of breast cancer as discussed above lend
themselves well to formation of groups of well educated,
middle class breast cancer survivors. Hence, multiple and
highly influential breast cancer groups do exist; they lobby
politicians, take government organizations to court and even
appeal to the European Court of Human Rights. This makes
those with control of budgets sit up and take notice.
In recent years advocacy groups have appeared representing
the other common cancers. Survivorship is less common and
less long lasting in these diseases. It is hard to form a pressure
group if all the sufferers are dead! These advocacy groups are
nowhere near as numerous or advanced in their efforts, but
perhaps they will also be a catalyst for change in the future.
If we turn our attention to the research budget the same is
true. Breast cancer research is very well funded and always
has been. This has a number of interlinked and inter-
dependent effects. More money leads to more research,
which leads to more researchers, which leads to more
advances, which leads to more therapies, which leads to
more publicity, which leads to more therapeutic options,
which leads to more survivors, which leads to more advocacy
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groups, which leads to more fundraising for research, and so
on. It is simple to appreciate how this cycle feeds off itself in
a positive loop.
Unfortunately, this loop has a number of missing parts in the
other diseases. Breakthroughs in prostate cancer are
uncommon. Survival from aggressive disease is very rare and
the disease affects elderly men, who are not efficient as
advocates. Colorectal cancer sufferers are loath to discuss
their disease in public; it somehow still has more stigma
attached to it than does breast cancer.
Is this situation morally justifiable? What can we do about
this? Should we try to do anything? These are difficult
questions, for which I believe there are no real answers. If one
develops a cancer, then that cancer is the most important
one to you. Therefore, if breast cancer patients can influence
the scene in this way, then perhaps we should not be
surprised. It is true that breast cancer therapy has moved
forward more than the others have over the past 20 years, so
it may be that patient advocacy works. Hence, rather than
complain about this, we perhaps should all just join in and
make the same happen for every cancer.
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